Document Detail


Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
MedLine Citation:
PMID:  22314264     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Lobaplatin as a single agent and in combination with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is investigated in in-vitro models of p53-negative triple-negative breast cancers (TNBCs) and compared with a model of oestrogen receptor-positive p53-positive breast cancer. In addition, the induction of programmed cell death by lobaplatin is further explored. By using cell viability assays and western blotting, the cytotoxic effects of lobaplatin alone and in combination with TRAIL are compared with cisplatin in HCC 1806, HCC 1937, and MCF 7 cells. The multicaspase inhibitor z-VAD-fmk and necrostatin, an inhibitor of necroptosis, are used to demonstrate the mechanism of cell death caused by lobaplatin. Lobaplatin displayed antitumour activity in all three cell lines, which increased time dependently. Cotreatment of lobaplatin and TRAIL induced an increase in cytotoxicity by 30-50% in the different cell lines. The pan-caspase inhibitor z-VAD-fmk as well as necrostatin could weaken but not abolish the cytotoxic effect of lobaplatin and cisplatin. Lobaplatin showed substantial cytotoxic effects in two in-vitro models of p53-mutated TNBC. Cotreatment with TRAIL and platinum agents resulted in increased antitumour activity in the TNBC cell lines investigated. Cell death subsequent to treatment with cisplatin and lobaplatin occurred because of apoptosis. However, caspase-independent mechanisms of programmed cell death were also involved. It was also demonstrated that platinum compounds could induce necroptosis, although to a minor extent.
Authors:
Jörg B Engel; Theresa Martens; Jens C Hahne; Sebastian F M Häusler; Mathias Krockenberger; Sabine Segerer; Antonia Djakovic; Susanne Meyer; Johannes Dietl; Jörg Wischhusen; Arnd Honig
Related Documents :
3614364 - Alternative rna splicing affects function of encoded platelet-derived growth factor a c...
3486454 - Induction of concanavalin a dose-dependent t-cell growth factor production by insertion...
2226304 - Intercellular propagation of individually programmed growth bursts in frtl-5 cells. imp...
15095284 - Fibroblast growth factor-2 over-rides insulin-like growth factor-i induced proliferatio...
8069864 - Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death ...
9566974 - Vinculin is part of the cadherin-catenin junctional complex: complex formation between ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-5
Journal Detail:
Title:  Anti-cancer drugs     Volume:  -     ISSN:  1473-5741     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Obstetrics and Gynecology, University of Würzburg, Würzburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy and Safety of Dextromethorphan/Quinidine at Two Dosage Levels for Diabetic Neuropathic Pain...
Next Document:  Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anti...